Current cancer situation in China: Good or bad news from the 2018 Global Cancer Statistics?
TLDR
China is undergoing the cancer transition stage where the cancer spectrum is changing from developing country to developed country, with a rapidly increase cancer burden of colorectal, prostate, female breast cancers in addition to a high occurrence of infection-related and digestive cancers.Abstract:
Cancer is the leading cause of death in China and depicting the cancer pattern of China would provide basic knowhows on how to tackle it more effectively. In this study we have reviewed several reports of cancer burden, including the Global cancer statistics 2018 and Cancer statistics in China, 2015, along with the GLOBCAN 2018 online database, to investigate the differences of cancer patterns between China, the United States (USA) and the United Kingdom (UK). An estimated 4.3 million new cancer cases and 2.9 million new cancer deaths occurred in China in 2018. Compared to the USA and UK, China has lower cancer incidence but a 30% and 40% higher cancer mortality than the UK and USA, among which 36.4% of the cancer-related deaths were from the digestive tract cancers (stomach, liver, and esophagus cancer) and have relatively poorer prognoses. In comparison, the digestive cancer deaths only took up ≤ 5% of the total cancer deaths in either USA or UK. Other reasons for the higher mortality in China may be the low rate of early-stage cancers at diagnosis and non-uniformed clinical cancer treatment strategies performed by different regions. China is undergoing the cancer transition stage where the cancer spectrum is changing from developing country to developed country, with a rapidly increase cancer burden of colorectal, prostate, female breast cancers in addition to a high occurrence of infection-related and digestive cancers. The incidence of westernized lifestyle-related cancers in China (i.e. colorectal cancer, prostate, bladder cancer) has risen but the incidence of the digestive cancers has decreased from 2000 to 2011. An estimated 40% of the risk factors can be attributed to environmental and lifestyle factors either in China or other developed countries. Tobacco smoking is the single most important carcinogenic risk factor in China, contributing to ~ 24.5% of cancers in males. Chronic infection is another important preventable cancer contributor which is responsible for ~ 17% of cancers. Comprehensive prevention and control strategies in China should include effective tobacco-control policy, recommendations for healthier lifestyles, along with enlarging the coverage of effective screening, educating, and vaccination programs to better sensitize greater awareness control to the general public.read more
Citations
More filters
Journal ArticleDOI
Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020.
TL;DR: China is undergoing cancer transition with an increasing burden of lung cancer, gastrointestinal cancer, and breast cancers, and the burden of breast cancer is increasing globally.
Journal ArticleDOI
A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group.
Humaid O. Al-Shamsi,Waleed Alhazzani,Ahmad Alhuraiji,Eric A. Coomes,Roy F. Chemaly,Meshari Almuhanna,Robert A. Wolff,Nuhad K. Ibrahim,Melvin L.K. Chua,Sebastien J. Hotte,Brandon M. Meyers,Tarek Elfiki,Giuseppe Curigliano,Cathy Eng,Axel Grothey,Conghua Xie +15 more
TL;DR: The potential challenges associated with managing cancer patients during the COVID‐19 infection pandemic will be addressed, with suggestions of some practical approaches.
Journal ArticleDOI
Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer
Huiyan Luo,Qi Zhao,Wei Wei,Lianghong Zheng,Shaohua Yi,Gen Li,Wenqiu Wang,Hui Sheng,Heng-Ying Pu,Hai-Yu Mo,Zhixiang Zuo,Zexian Liu,Li Chaofeng,Chuanbo Xie,Zhao-Lei Zeng,Weimin Li,Xiaoke Hao,Yuying Liu,Sumei Cao,Wanli Liu,Sarah Gibson,Kang Zhang,Kang Zhang,Guoliang Xu,Rui-Hua Xu +24 more
TL;DR: The authors identified and validated a methylation-based diagnostic score to help distinguish patients with colorectal cancer from healthy controls, as well as a prognostic score that correlated with patients’ survival, and found that a single ctDNA methylation marker could yield high sensitivity and specificity for identifying patients with cancer.
Journal ArticleDOI
Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020.
Haibo Qiu,Sumei Cao,Rui-Hua Xu +2 more
TL;DR: Wang et al. as discussed by the authors reviewed the rates and trends of cancer incidence and mortality and disability-adjusted life year (DALY) burden in China, and compared them with those in the United States (US) and the United Kingdom (UK).
Journal ArticleDOI
Cancer burden of major cancers in China: A need for sustainable actions
TL;DR: The incidence of the five most common cancers, in China, in 2015, including cancers of the lungs, stomach, colorectum, liver and breast, accounted for almost 60% of all cancers diagnosed.
References
More filters
Journal ArticleDOI
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray,Jacques Ferlay,Isabelle Soerjomataram,Rebecca L. Siegel,Lindsey A. Torre,Ahmedin Jemal +5 more
TL;DR: A status report on the global burden of cancer worldwide using the GLOBOCAN 2018 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer, with a focus on geographic variability across 20 world regions.
Journal ArticleDOI
Cancer statistics in China, 2015
Wanqing Chen,Rongshou Zheng,Peter D. Baade,Siwei Zhang,Hongmei Zeng,Freddie Bray,Ahmedin Jemal,Xue Qin Yu,Jie He +8 more
TL;DR: Many of the estimated cancer cases and deaths can be prevented through reducing the prevalence of risk factors, while increasing the effectiveness of clinical care delivery, particularly for those living in rural areas and in disadvantaged populations.
Journal ArticleDOI
Current Cigarette Smoking Among Adults - United States, 2016.
Ahmed Jamal,Elyse Phillips,Andrea S. Gentzke,David M. Homa,Stephen Babb,Brian A. King,Linda J. Neff +6 more
TL;DR: To assess progress toward the Healthy People 2020 target of reducing the proportion of U.S. adults aged ≥18 years who smoke cigarettes to ≤12.0% (objective TU-1.1), the CDC analyzed data from the 2016 National Health Interview Survey (NHIS) and found that the prevalence of current cigarette smoking among adults was 15.5%, which was a significant decline from 2005 but no significant change has occurred since 2015.
Journal ArticleDOI
Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study
Silvia de Sanjosé,Wim Quint,Laia Alemany,D.T. Geraets,Jo Ellen Klaustermeier,Belen Lloveras,Sara Tous,Ana Félix,Luis Eduardo Bravo,Hai Rim Shin,Carlos S. Vallejos,Patricia Alonso de Ruiz,Marcus Aurelho Lima,Núria Guimerà,Omar Clavero,Maria Alejo,Antonio Llombart-Bosch,Chou Cheng-Yang,Silvio Tatti,Elena Kasamatsu,Ermina Iljazovic,Michael Odida,Rodrigo Prado,Muhieddine Seoud,Magdalena Grce,Alp Usubutun,Asha Jain,Gustavo Adolfo Hernandez Suarez,Luis Estuardo Lombardi,Aekunbiola Banjo,Clara Menendez,Efren J. Domingo,Julio Velasco,Ashrafun Nessa,Saibua Chichareon,You-Lin Qiao,Enrique Lerma,Suzanne M. Garland,Toshiyuki Sasagawa,Annabelle Ferrera,Doudja Hammouda,Luciano Mariani,Adela Pelayo,Ivo Šteiner,Esther Oliva,Chris J. L. M. Meijer,Waleed Al-Jassar,Eugenia Cruz,Thomas C. Wright,Ana Puras,Cecilia L. Llave,Maria Tzardi,Theodoros Agorastos,Victoria Garcia-Barriola,Christine Clavel,Jaume Ordi,Miguel Andújar,Xavier Castellsagué,Gloria I. Sanchez,Andrzej Nowakowski,Jacob Bornstein,Nubia Muñoz,F. Xavier Bosch +62 more
TL;DR: HPV types 16, 18, 31, 33, 35, 45, 52, and 58 should be given priority when the cross-protective effects of current vaccines are assessed, and for formulation of recommendations for the use of second-generation polyvalent HPV vaccines, according to this largest assessment of HPV genotypes to date.